CLINICAL TRIALS PROFILE FOR NETUPITANT
✉ Email this page to a colleague
Clinical Trials for Netupitant
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01339260 ↗ | An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting | Completed | Parexel | Phase 3 | NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy. |
NCT01339260 ↗ | An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting | Completed | Helsinn Healthcare SA | Phase 3 | NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy. |
NCT01376297 ↗ | A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting | Completed | Parexel | Phase 3 | NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy. |
NCT01376297 ↗ | A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting | Completed | Helsinn Healthcare SA | Phase 3 | NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy. |
NCT02517021 ↗ | A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting | Completed | PSI CRO | Phase 3 | NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy. |
NCT02517021 ↗ | A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting | Completed | PSI CRO AG | Phase 3 | NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Netupitant
Condition Name
Condition Name for | |
Intervention | Trials |
Chemotherapy-Induced Nausea and Vomiting | 9 |
Malignant Neoplasm | 2 |
Chemotherapy-induced Nausea and Vomiting (CINV) | 1 |
Hematopoietic Cell Transplantation Recipient | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for Netupitant
Trials by Country
Clinical Trial Progress for Netupitant
Clinical Trial Phase
Clinical Trial Sponsors for Netupitant
Sponsor Name